PMGC Holdings EBIT Margin

What does PMGC Holdings do? ELEVAI Labs Inc generates revenue through its physician-dispensed skincare products, primarily featuring the Elevai Exosomes technology. The company's Precision Regenerative Exosome Technology (PREx) produces exosome lots from human umbilical cord-derived mesenchymal stem cells for its specialty products. Its initial product line, Elevai Post Treatment E-Series, includes Empower and Enfinity serums designed for post-skincare procedure care targeting the face, neck, and upper chest. The products are sold directly to physicians who dispense them to patients as part of medical aesthetics treatments. The company focuses on the medical aesthetics industry, where its products complement professional skincare procedures. Physicians purchase Elevai's serums to offer patients enhanced skin appearance solutions following treatments. The E-Series targets specific areas requiring post-procedure care, with Empower supporting healthy skin appearance and Enfinity providing specialized care for the face, neck, and upper chest regions. The firm's research and development efforts drive the commercialization of these science-driven topical skincare solutions. ELEVAI Labs Inc's business model centers on physician-dispensed products within the medical aesthetics sector. The company's proprietary PREx biotechnology process enables the production of exosome-based skincare, which is integrated into its initial product line. The products are marketed as complementary solutions for patients undergoing medical aesthetic procedures, with physicians acting as the primary buyers who distribute them to end users. PMGC Holdings is one of the most popular companies on Eulerpool.